GlaxoSmithKline (GSK) has released an update.
GlaxoSmithKline (GSK) has announced that their Shingrix vaccine, designed to prevent shingles in adults aged 50 and over, has maintained high efficacy rates of up to 82% even after 11 years post-vaccination, according to the ZOSTER-049 phase III trial. The trial’s end data, which included over 7,000 participants, revealed no new safety concerns, supporting Shingrix’s role in long-term shingles prevention. These findings are poised to bolster confidence in public immunization strategies, with shingles affecting up to one in three people globally during their lifetime.
For further insights into GSK stock, check out TipRanks’ Stock Analysis page.
